Meet us at BIO International Convention 2022

Supporting the fight against COVID-19

Learn how Sciomics supports COVID-19 research

 

Accelerated research is the best opportunity to increase the understanding of COVID-19 disease and efficiently fighting the novel coronavirus SARS-CoV-2. Testing multiple proteins in parallel accelerates your research and enables in-depth insights regarding the underlying molecular mechanisms.

 

Learn here how multiplex protein profiling can support your COVID-19 research. All information is also available as a pdf.

 

 

   Immune Response Profiling & Biomarker Discovery

> Immune Response Profiling

Explore how the immune system reacts to a SARS-CoV-2 infection in different age groups, risk groups and certain individuals. Are there common mechanisms which can be used for preventing severe disease ?  A parallel profiling of 121 cytokines / chemokines and 141 cell surface markers can provide novel insights. Such analyses are possible from patient samples (plasma / serum), cell culture as well as animal models.

> Disease Severity biomarkers for COVID-19

Discover new biomarkers for COVID-19 patient stratification, early prevention and improvement of disease management by multiplex screens from plasma or serum samples.
< scioDiscover >

> Outcome Prediction after positive SARS-CoV-2 test

Identify risk factors and correlating protein biomarkers indicating severe COVID-19 progression for improved disease management.
< scioDiscover >

 

    Development of therapeutics against COVID-19

> Benchmarking of Therapeutics & Drug Repurposing

Accelerate your COVID-19 research by assessing pathway activity, early toxicology and mechanisms of action for an efficient benchmarking of compounds or drug repurposing candidates.
< scioDiscover >  < scioPhospho >

> Therapy Response biomarkers

Identify predictive biomarkers for your COVID-19 drug candidate to stratify responders from non-responders
< scioDiscover >

 

   Development of vaccines against SARS-CoV-2

> SARS-CoV-2 vaccine development

In-depth analysis of responses to vaccine candidates from animal and patient samples. Analyses are possible from plasma / serum samples or from purified immune cells.
< scioCD >  < scioDiscover >  < scioPhospho >

> Profiling of animal models

Characterize response in different model organisms (mouse, rat and more) for your SARS-CoV-2 vaccine development
< scioDiscover >  < scioPhospho >

> Screening of viral SARS-CoV-2 epitopes

Analyse the antibody response to different vaccine candidates in animal models and patients using plasma/serum samples.
Analyse serum samples from COVID-19 patients to identify highly immunogenic epitopes.

 

   Assays available

scioCD - 121 cytokines and 141 CD cell surface markers for immune profiling

Parallel profiling of 121 cytokines / chemokines and 141 CD cell surface markers from plasma/serum, immune cells or tissue samples.

scioDiscover - screening of 1,300 proteins in parallel

The protein panel for biomarker discovery on plasma/serum, cell or tissue samples include

  • inflammatory mediators
  • immune checkpoint molecules
  • immune cells markers
  • soluble proteins
  • membrane/receptor proteins
  • intracellular proteins

< more information >

scioPhospho - combined phosphorylation and expression profiling of 1,300 proteins

Combine a scioDiscover screen with information on phosphorylation status for all 1,300 proteins in one assay. Typical applications are mode-of-action studies, pathway activity profiling or mechanistic understanding of disease as well as therapeutic response.
< more information >


Common assay specifications

  • Minimal sample amount required (20 µL plasma/serum, 500,000 cells, 10mg of tissue)
  • Complete analysis service from sample to study report
  • All assays can be complemented by a SARS-CoV-2 proteome wide peptide array < more information >

 

   Get in touch with our scientific team

Phone + 49 (0) 6221 4294830                                                                
This email address is being protected from spambots. You need JavaScript enabled to view it.

covid 19 immuneResponse v2 web

Our service portfolio

scioPhospho: protein profiling and phosphorylation status

scioPhospho: protein profiling and phosphorylation status

scioPhospho combines the advantages of a robust and cost-efficient protein expression profiling using scioDiscover with information on phosphorylation status. This combination provides a comprehensive overview on signalling events and pathway activity regulation. Features 1,300 highly relevant proteins are profiled in a single assay Phosphorylation status combined with protein expression levels…
Read more
scioDiscover - Protein Profiling on expression level

scioDiscover - Protein Profiling on expression level

Knowledge about protein expression levels is of utmost importance to predict toxic effects, estimate adverse effects of drug candidates and to identify new drug targets. Sciomics has a highly optimised…
scioCD - Cell surface marker and Cytokine profiling

scioCD - Cell surface marker and Cytokine profiling

  Characterise a certain cell type?   Cell composition in a certain tissue sample?   In-depth profiling of CD-marker expression?   Increase your throughput at high sensitivity levels? You aim…
scioUbi

scioUbi

Protein & ubiquitination profiling scioUbi is a high-content protein expression and ubiquitination level analysis. With scioUbi you can analyse up to 1,000 proteins in a single assay.   Features Screen…
scioCyto : Cytokine profiling

scioCyto : Cytokine profiling

scioCyto : Cytokine profiling scioCyto is a high-content analysis service for multiplex cytokine and chemokine profiling on protein level. A great variety of samples such as plasma, tissue, cells or…

COVID-19 related activities and services

covid 19 portfolio web

News

New article | Co-Expression of microRNAs and Proteins in Alzheimer’s Disease

| Jan 2022 | In a study by Valentina di Pietro at Birmingham University our scioDoiscover platform was used to analyse the co-expression of proteins and microRNAs in the brains of Alzheimer's disease patients.

Watson, C. N. et al. Co-Expression Analysis of microRNAs and Proteins in Brain of Alzheimer’s Disease Patients. Cells 11, 163 (2022).
New article | ETV6 levels predict outcome in DLBCL

| Jan 2022 | Erich Piovan and collegues at University of Padua collaborated with Sciomics to study specific biomarkers in FFPE tissue samples of DLBCL patients by custom antibody microarrays.

Marino, D. et al. High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients. Cancers 14, (2022).
New article | Biomarker identification and verification in endometriosis

| 22th Oct 2021 | Scientists at University Medical Centre Ljubljana used our scioDiscover platform for a biomarker identification in endometriosis:

"Discovery proteomics using antibody microarrays that covered 1360 proteins identified 16 proteins with different levels in cases versus the control patients. The validation using an ELISA approach confirmed significant differences in the levels of cartilage oligomeric matrix protein (COMP) and transforming growth factor-β-induced protein ig-h3 (TGFBI) and nonsignificant differences in angiotensinogen (AGT). "

 Janša, V. et al. (2021) ‘Proteomic analysis of peritoneal fluid identified COMP and TGFBI as new candidate biomarkers for endometriosis’, Scientific Reports, 11:20870. doi: 10.1038/s41598-021-00299-2. 

biomarkers in endometriosis

 

New article | Parkinson's Disease analysed via brain organoids

| Oct 2021 | In a study led by University of Luxembourg and OrganoTherapeutics SARL-S we used our scioPhospho assay to analyse the reaction of a brain organoid model for Parkinson's disease to certain treatments.

Jarazo, J. et al. (2021) ‘Parkinson's Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by 2-Hydroxy...’, Movement Disorders, in press: doi: 10.1002/mds.28810 (Please get in touch for fulltext).

 

New article | Selective elimination of immunosuppressive T cells in patients with multiple myeloma

| Feb 2021 | Scientists at Heidelberg University Hospital used our scioCD  platform to profile CD8+SLAMF7+ cell cultures:

"High throughput screening of 351 different cytokines and immune proteins in the supernatants of the T cells cultures revealed strong upregulation of IL-6, IL-8, both vital survival factors for myeloma cells, and CXCL5, a chemokine that could enhance the frequency of CD4 Treg, in the cultures containing CD8+SLAMF7+ cells. IL-2 and IL-5 were upregulated in the control cultures without CD8+SLAMF7+ T cells, highlighting a more activated state in the control group and suggestion IL-6 and IL-8 as potential effector cytokines for the suppressive CD8+SLAMF7+ T cells."

Awwad, M. H. S. et al. (2021) ‘Selective elimination of immunosuppressive T cells in patients with multiple myeloma’, Leukemia, pp. 1–14. doi: 10.1038/s41375-021-01172-x.

 

Testimonials

Dr. Joachim Lupberger 

Institute for Viral and Liver Disease, Inserm U1110, University of Strasbourg, LabEx HepSYS, Strasbourg, France

"Our lab is focusing on the identification of minimal-invasive biomarkers for liver disease progression. A challenge of our humanized animal models for liver disease is the low volume of blood samples available, which did not pose any problem for the analysis. I was pleased by the prompt, friendly, and uncomplicated contact and was impressed by the results and the thorough report we received. The overall quality was excellent, which made us to continue using the service of Sciomics for follow-up projects analyzing patient material."

Product: scioPhospho

 

 Prof. Dr. Andreas Weigert 

Goethe-University Frankfurt, Faculty of Medicine, Institute of Biochemistry I, Frankfurt, Germany

"We were under considerable time pressure to gain comprehensive information about cytokine/chemokine levels in a mouse model of self-resolving inflammation. To add to our misery, we had only a small number of biological replicates to run the analyses. Thankfully, the team at Sciomics were able to come to our rescue by providing a very prompt analysis, without neglecting to properly communicate the procedure, potential caveats and other details. The whole process was a very satisfying experience, rather like working with committed colleagues than with a company, and we got great data out of the project. I do happily recommend working with Sciomics for targeted proteomics analyses."

Product: scioCD

 

Tweets

  • 6 days ago

    Partner with us at #BIO2022 International Convention in San Diego CA and learn about our smart protein biomarker po… https://t.co/kYObhmyG1B

  • 6 days ago

    RT @Fusion_Conf: Final day of the 3rd Cell Death, Cell Stress & Metabolism Conference. We are looking forward to more outstanding talks thi…

  • 6 days ago

    We are here for the 3rd and final day of the 3rd Cell Death, Cell Stress & Metabolism Conference #CDCSM22, at Cancu… https://t.co/g8MUcdyEkm

  • 10 days ago

    En-route to attending 3rd Cell Death, Cell Stress & Metabolism Conference #CDCSM22 Dr Anne Griesbeck will be giving… https://t.co/JrXTQGQoj3

  • 42 days ago

    We would like to welcome our new colleague Barbara Eberbach in our team. Barbara is experienced in setting up new v… https://t.co/VC3S3QXYFL